JAZZ FY 2023 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.8B+4.8% YoY

Gross Profit

$3.4B88.6% margin

Operating Income

$579M15.1% margin

Net Income

$415M10.8% margin

EPS (Diluted)

$6.10

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$1.1B

Stock-Based Comp.

$227M

Balance Sheet

Total Assets

$11.4B

Total Liabilities

$7.7B

Stockholders' Equity

$3.7B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.7B	+4.8%
Gross Profit	$3.4B	$3.1B	+9.0%
Operating Income	$579M	-$66M	+983.0%
Net Income	$415M	-$224M	+285.1%